spironolactone has been researched along with Cerebrovascular Disorders in 6 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone did not enhance water and electrolyte excretion." | 1.30 | Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. ( Chander, PN; Khanna, K; Rocha, R; Stier, CT; Zuckerman, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, T | 1 |
| Nishiwaki, H | 1 |
| Ota, E | 1 |
| Levack, WM | 1 |
| Noma, H | 1 |
| Rocha, R | 1 |
| Chander, PN | 1 |
| Khanna, K | 1 |
| Zuckerman, A | 1 |
| Stier, CT | 1 |
| Wilhelmsen, L | 1 |
| Berglund, G | 1 |
| Sannerstedt, R | 1 |
| Hansson, L | 1 |
| Andersson, O | 1 |
| Sievertsson, R | 1 |
| Wikstrand, J | 1 |
| Zweifler, AJ | 1 |
| Esler, M | 1 |
| Tomori, M | 1 |
| Nakazato, M | 1 |
| Kimura, Y | 1 |
| Muratani, H | 1 |
| Tsutsu, N | 1 |
| Noda, Y | 1 |
| Eto, T | 1 |
| Fukiyama, K | 1 |
| Kilcoyne, MM | 1 |
| Thomson, GE | 1 |
| Branche, G | 1 |
| Williams, M | 1 |
| Garnier, C | 1 |
| Chiles, B | 1 |
| Soland, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Trial of L-arginine and Spironolactone in Dialysis-dependant End Stage Renal Disease[NCT01855334] | Phase 4 | 0 participants (Actual) | Interventional | 2013-09-30 | Withdrawn (stopped due to change of funding leading to major redesign) | ||
| Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493] | Phase 3 | 33 participants (Actual) | Interventional | 2014-11-07 | Completed | ||
| Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies[NCT00277693] | Phase 4 | 0 participants | Interventional | Recruiting | |||
| Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease[NCT03020303] | Phase 3 | 2,750 participants (Anticipated) | Interventional | 2017-07-07 | Recruiting | ||
| [NCT01687699] | Phase 4 | 157 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Subjects With Severe Heart Failure and End-Stage Renal Disease on Hemodialysis: A Pilot Study to Assess Safety and Tolerability of Spironolactone[NCT00328809] | Phase 4 | 0 participants (Actual) | Interventional | 2013-06-30 | Withdrawn (stopped due to personnel shortage) | ||
| Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease (ESRD) (SPin-D) Trial[NCT02285920] | Phase 2 | 129 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Role of Renin Angiotensin Blockade in Peritoneal Fibrosis in Peritoneal Dialysis Patients[NCT00865449] | Phase 3 | 20 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients[NCT01128101] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Continuous Ambulatory Peritoneal Dialysis Patients: An Open-Label Randomized-Controlled Trial[NCT03953950] | Phase 4 | 84 participants (Anticipated) | Interventional | 2019-10-31 | Not yet recruiting | ||
| The Effects of Losartan and Spironolactone on Residual Renal Function Preservation in Peritoneal Dialysis Patients[NCT02190318] | 96 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | |||
| ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b[NCT01848639] | Phase 3 | 823 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.[NCT02490904] | Phase 3 | 132 participants (Anticipated) | Interventional | 2016-10-19 | Active, not recruiting | ||
| Pilot Trial of Hemodialysis Patient Aldosterone antagoniSm With Eplerenone Trial[NCT01650012] | 158 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Phase II Trial to Evaluate the Efficacy and Safety of Spironolactone in Hemodialysis Patients[NCT01691053] | Phase 2 | 118 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of Cardiovascular deaths defined as death due to myocardial infarction, congestive heart failure, cardiac valvular disease, arrhythmia, sudden death, stroke, or peripheral arterial disease (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 1 |
| Spironolactone 12.5 mg | 0 |
| Spironolactone 25 mg | 2 |
| Spironolactone 50 mg | 1 |
The number of participants who had serum potassium >6.5 mEq/L or serious hyperkalemia was assessed by treatment arm. (NCT02285920)
Timeframe: 0 - 40 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 13 |
| Spironolactone 12.5 mg | 5 |
| Spironolactone 25 mg | 5 |
| Spironolactone 50 mg | 10 |
Hyperkalemia requiring adjustment in dialysate potassium concentration, or discontinuation of study medication (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 13 |
| Spironolactone 12.5 mg | 2 |
| Spironolactone 25 mg | 5 |
| Spironolactone 50 mg | 7 |
Number of patients with serious hyperkalemia requiring hospitalization, emergency/unscheduled dialysis or resin therapy (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 6 |
| Spironolactone 12.5 mg | 2 |
| Spironolactone 25 mg | 0 |
| Spironolactone 50 mg | 7 |
The number of participants who had serum potassium >6.5 mEq/L was assessed by treatment arm. (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Spironolactone 12.5 mg | 4 |
| Spironolactone 25 mg | 4 |
| Spironolactone 50 mg | 8 |
The number of participants experiencing serious hypotension, defined as hypotension requiring hospitalization or ED visit and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Spironolactone 12.5 mg | 2 |
| Spironolactone 25 mg | 0 |
| Spironolactone 50 mg | 3 |
Tolerability is defined as number of participants who experienced permanent study drug discontinuation or dose reduction. (NCT02285920)
Timeframe: 0 - 36 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 16 |
| Spironolactone 12.5 mg | 5 |
| Spironolactone 25 mg | 6 |
| Spironolactone 50 mg | 8 |
Change in mitral annular E' velocity measured using Tissue Doppler Index (TDI) echocardiography. Efficacy outcomes were considered exploratory with a goal of detecting signals rather than clearly demonstrating efficacy. (NCT02285920)
Timeframe: Baseline to 36 weeks
| Intervention | cm/second (Mean) | ||
|---|---|---|---|
| Baseline MA E' | 36 Week MA E' | Change between baseline - 36 weeks | |
| Placebo | 7.4 | 7.5 | 0.1 |
| Spironolactone 12.5 mg | 7.6 | 7.4 | -0.2 |
| Spironolactone 25 mg | 7.8 | 7.7 | -0.1 |
| Spironolactone 50 mg | 7.0 | 7.3 | 0.3 |
"Secondary outcome measures include other echocardiographic markers of systolic and diastolic function~• Change in left ventricular ejection fraction between Baseline and 36 weeks" (NCT02285920)
Timeframe: Baseline - 36 weeks
| Intervention | percent ejection fraction (Mean) | ||
|---|---|---|---|
| LVEF Baseline | LVEF 36-Week | LVEF Change | |
| Placebo | 68.9 | 70.7 | 1.8 |
| Spironolactone 12.5 mg | 65.9 | 66.9 | 1.0 |
| Spironolactone 25 mg | 66.0 | 65.3 | -0.7 |
| Spironolactone 50 mg | 68.2 | 69.5 | 1.3 |
"Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,~• Change in myocardial strain and strain rate between baseline and 36 weeks" (NCT02285920)
Timeframe: Baseline - 36 weeks
| Intervention | % of myocardial shortening (Mean) | ||
|---|---|---|---|
| LVGLS Baseline | LVGLS 36-week | LVGLS Change | |
| Placebo | -17.2 | -18.1 | -0.8 |
| Spironolactone 12.5 mg | -16.7 | -17.0 | -0.3 |
| Spironolactone 25 mg | -17.2 | -17.0 | 0.2 |
| Spironolactone 50 mg | -17.4 | -18.2 | -0.7 |
"Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,~• E/E' is the ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E')" (NCT02285920)
Timeframe: Baseline - 36 weeks
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| E/E' Baseline | E/E' 36-Week | E/E' Change | |
| Placebo | 10.7 | 11.5 | 0.9 |
| Spironolactone 12.5 mg | 11.8 | 12.2 | 0.4 |
| Spironolactone 25 mg | 9.2 | 10.6 | 1.4 |
| Spironolactone 50 mg | 12.5 | 11.9 | -0.6 |
"Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,~• Change in left ventricular mass index (LVMI) between baseline and 36 weeks" (NCT02285920)
Timeframe: Baseline - 36 weeks
| Intervention | g/m^2 (Mean) | ||
|---|---|---|---|
| LVMI Baseline | LVMI 36-Week | LVMI Change | |
| Placebo | 105.2 | 94.8 | -10.4 |
| Spironolactone 12.5 mg | 115.5 | 104.6 | -10.9 |
| Spironolactone 25 mg | 116.4 | 109.1 | -7.3 |
| Spironolactone 50 mg | 106.3 | 96.5 | -9.8 |
1 review available for spironolactone and Cerebrovascular Disorders
| Article | Year |
|---|---|
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
5 other studies available for spironolactone and Cerebrovascular Disorders
| Article | Year |
|---|---|
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
Topics: Aging; Animals; Body Weight; Brain; Cerebrovascular Disorders; Delayed-Action Preparations; Diuresis | 1998 |
Effect of treatment of hypertension in the primary preventive trial, Göteborg, Sweden.
Topics: Adrenergic beta-Antagonists; Bethanidine; Cardiovascular Diseases; Cerebrovascular Disorders; Corona | 1979 |
Factors influencing the choice of antihypertensive agents.
Topics: Age Factors; Aldosterone; Cerebrovascular Disorders; Clonidine; Depression; Diabetes Complications; | 1976 |
[Hyperaldosteronism and cerebrovascular disease; report of 4 cases].
Topics: Adult; Cerebrovascular Disorders; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Renin | 1988 |
Characteristics of hypertension in the black population.
Topics: Adult; Angiotensin II; Animals; Black or African American; Cardiomegaly; Cerebrovascular Disorders; | 1974 |